The main goal of the deal is to bring Azora's lead drug candidate, called AT177, into Adial's pipeline. Adial expects to begin the first human clinical trial for the experimental drug in mid-2027. The ...
The news from Adial Pharmaceuticals (NASDAQ: ADIL) has to do with the company's AD04 asset. This is a drug from the company that is used to treat individuals suffering from alcohol use disorder. The ...
Adial Pharmaceuticals ( (ADIL)) has shared an announcement. On August 1, 2025, shareholders of Adial Pharmaceuticals approved a reverse stock split of the company’s common stock, and the board later ...
Get up to 10 years of daily historical stock prices & volumes. Data provided by Edgar Online. ©2021, EDGAR®Online, a division of Donnelley Financial Solutions ...
Adial Pharmaceuticals ( (ADIL)) has issued an update. On January 5, 2025, Adial Pharmaceuticals announced that James W. Newman, Jr., a non-employee director and member of both the Audit Committee and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results